Proteome Sciences plc

Equities

PRM

GB0003104196

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 11:35:16 2024-05-10 am EDT			5-day change	1st Jan Change
3.45 ^GBX	+2.68%		-1.71%	-23.84%

Apr. 26	Proteome Sciences Wins GBP500,000 Spectrometry Services Contract in US	MT
Apr. 26	Proteome wins GBP500,000 deal to supply mass spectrometry services	AN

Proteome Sciences plc Names Jeremy Haigh as Chief Executive Officer, Effective from June 2016

May 18, 2016 at 02:01 am EDT

Proteome Sciences plc announced that Jeremy Haigh will be joining the board as CEO in June 2016 (subject to regulatory approval). He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role. Jeremy is an established leader in the biopharmaceutical sector with 30 years in clinical and operational research and development, principally at Merck and Amgen where most recently he was European Chief Operating Officer, R&D. He is currently the Chairman of Cogent Skills Limited and a member of Imperial College Health Partners Advisory Council.

Latest news about Proteome Sciences plc

Proteome Sciences Wins GBP500,000 Spectrometry Services Contract in US	Apr. 26	MT
Proteome wins GBP500,000 deal to supply mass spectrometry services	Apr. 26	AN
AIM WINNERS & LOSERS: Proteome Sciences rises on GBP500,000 contract	Apr. 26	AN
Thoma Bravo snaps up Darktrace for USD5 billion	Apr. 26	AN
Proteome Sciences plc Secures Contract from US Biopharmaceutical Company	Apr. 26	CI
Proteome Sciences shares drop as revenue plunges and swings to loss	Apr. 10	AN
Proteome Sciences plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Proteome Sciences Completes New US Lab Setup	Jan. 02	MT
Proteome Sciences Announces the Completion of Installation and Setup of Equipment in Its New US Laboratory in San Diego, California	Jan. 02	CI
Proteome Sciences says San Diego lab now fully operational	Jan. 02	AN
AIM WINNERS & LOSERS: Totally slides again; Proteome warns on earnings	Nov. 30	AN
Proteome Sciences shares drop as cuts annual revenue outlook	Nov. 30	AN
Proteome Sciences sees shares surge on SysQuant service launch	23-10-02	AN
Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro? Isobaric Labelling Reagents	23-10-02	CI
FTSE 100 Finishes Flat After Choppy Week	23-08-25	DJ
UK 2063 Gilt Seen Attractively Valued Ahead of Syndicated Tap	23-08-25	DJ
FTSE 100 pushes higher ahead of Fed chair speech	23-08-25	AN
AIM WINNERS & LOSERS: Panthera Resources secures litigation financing	23-08-25	AN
Proteome Sciences shares fall as swings to interim loss on costs	23-08-25	AN
Earnings Flash (PRM.L) PROTEOME SCIENCES Posts H1 Loss GBX-0.20	23-08-25	MT
Proteome Sciences plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
OnTheMarket new CFO Tom Carter starts role	23-07-04	AN
Proteome Sciences repays GBP824,400 loan in full to Vulpes	23-06-01	AN
Brand Architekts CFO to Step Down in June; Successor Named	23-05-26	MT
FTSE 100 Closes Down 0.35% After Corporate Updates; Melrose Industries Shines on Guidance Lift	23-05-17	DJ

Chart Proteome Sciences plc

Duration

Period

More charts

Company Profile

Proteome Sciences plc is a specialist provider of contract proteomics services. The Companyâs services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PROTEOME SCIENCES PLC	-23.84%	12.74M
ABBOTT LABORATORIES	-4.84%	182B
MEDTRONIC PLC	+0.56%	110B
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B
DEXCOM, INC.	+2.39%	50.53B
CENCORA, INC.	+9.36%	44.8B
HOYA CORPORATION	+2.70%	40.7B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B
TERUMO CORPORATION	+13.67%	25.02B
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B

Other Medical Equipment, Supplies & Distribution